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Abstract
Background and Aims: Although terlipressin (TP) may improve renal function in cirrhotic patients, its use in sepsis remains
controversial due to concerns about regional ischemia. We investigated the effects of TP on regional hemodynamics and
kidney function in experimental hyperdynamic sepsis.
Methods: We studied thirteen merino ewes in a university physiology laboratory using a randomized controlled cross over
design. We implanted flow probes around the pulmonary, circumflex coronary, superior mesenteric, renal and iliac arteries.
We injected live Escherichia coli and induced hyperdynamic sepsis. We treated animals with either bolus vehicle or a single
dose of TP (sTP=1 mg). In a second group, after 1 mg of TP, two additional bolus injections (mTP) of 0.5 mg were given at 2
hourly intervals.
Main Results: sTP (1 mg) significantly increased mean arterial pressure (MAP) (74 to 89 mmHg; P,0.0001) creatinine
clearance (31 to 85 mL/min; P,0.0001) and urine output (24 to 307 mL/hr) (P,0.0001). However, it decreased CO (5.7 to
3.9 L/min; p,0.0001), coronary blood flow (CBF) (43 to 32 mL/min; p,0.0001) and mesenteric blood flow (MBF) (944 to
625 mL/min; p=0.004) and increased blood lactate (2.1 to 4.0 mmol/L; p,0.0001). Extra doses of TP caused little additional
effect.
Conclusions: In hyperdynamic sepsis, bolus TP transiently improves MAP and renal function, but reduces CO, CBF and MBF,
and increases blood lactate. Caution should be applied when prescribing bolus TP in septic patients at risk of coronary or
mesenteric ischemia.
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Introduction
Severe sepsis is a major cause of death in critically ill patients
and its incidence is increasing [1]. In septic patients,
catecholamines are frequently used to improve perfusion
pressure [2,3]. However, vascular hyporeactivity to catechol-
amines is common [4,5] suggesting the need to either use other
vasopressor agents or combine catecholamines with other
vasopressor agents. For example, arginine vasopressin (AVP),
which acts on vascular smooth muscle via V1 receptors [6], has
been used as an additional vasoactive drug in patients with
septic shock [2,7]. Such addition is postulated to also improve
kidney dysfunction in patients with septic shock [8]. However,
an agent with longer half life and greater V1 selectivity would
appear desirable.
Terlipressin (TP) is a synthetic analogue of AVP, with greater
selectivity for the V1 receptor and a longer half-life. TP has proved
efficacious in the treatment of the hepatorenal syndrome [9],
another condition characterized by marked systemic vasodilata-
tion and renal vasoconstriction (a state similar to sepsis). Given
such biological properties and efficacy in the hepatorenal
syndrome, intermittent intravenous boluses of TP have been used
to restore blood pressure in septic shock patients [4,10]. However,
serious adverse events have been reported and there is uncertainty
over its ability to replicate the potential beneficial effects of AVP
[11–13] and its safety in this setting. Such uncertainty derives, in
part, from the lack of controlled experimental data on its regional
effects.
We hypothesized that TP would reduce vital organ blood flow
in mammalian hyperdynamic sepsis and thus examined its effects
(both single and repeated administration) on systemic and regional
hemodynamics and kidney function in a sheep model of
hyperdynamic sepsis.
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Animal preparation
Experiments were completed on 13 adult Merino ewes (female
sheep) (28–37 kg) housed in individual metabolic cages, with free
access to food and water. The experimental procedures were
approved by the Animal Experimental Ethics Committee of the
Howard Florey Institute under guidelines laid down by the
National Health and Medical Research Council of Australia.
The animals underwent three sterile surgical procedures under
anesthesia at intervals of 2 weeks. Anesthesia was induced with
intravenous sodium thiopentone (15 mg/kg) for intubation with an
endotracheal tube (cuffed size 10). Maintenance of anesthesia was
by means of oxygen/air/isoflurane (1.5–2.0%). Fractional inspired
oxygen was altered to maintain PaO2 at approximately
100 mmHg, and ventilation was controlled to maintain PaCO2
at approximately 40 mmHg. First, double carotid arterial loops
were created to facilitate subsequent arterial cannulation. Second,
transit time flow probes (Transonics Systems, Ithaca, NY, USA)
were placed on the pulmonary artery and the left circumflex
coronary artery. Finally, transit time flow probes were placed on
the left renal artery, the superior mesenteric artery and the left
external iliac artery.
The animals were allowed at least two weeks to recover before
the start of experiments. In all operations, animals were treated
with intramuscular antibiotics (900 mg, Ilium Propen; procaine
penicillin, Troy Laboratories Ptd Ltd, Smithfield, NSW, Australia
or Mavlab, Qld, Australia) at the start of surgery and then for 2
days postoperatively. Post-surgical analgesia was maintained with
intramuscular injection of flunixin meglumine (1 mg/kg) (Troy
Laboratories or Mavlab, Qld, Australia) at the start of surgery,
then 4 and 16 hours post-surgery.
The day before the experiment, a Tygon catheter (Cole-
Parmers; Boronia, Australia; ID 1.0 mm, OD 1.5 mm) was
inserted into the carotid arterial loop to measure arterial pressure.
A polythene catheter (PortexH; Smiths Medical International Ltd.
Hythe, Kens UK; ID 1.19 mm, OD 1.70) was inserted into a
jugular vein for measurement of central venous pressure and
infusion. Analog signals (mean arterial pressure (MAP), heart rate,
cardiac output (CO) and vital organ blood flow (coronary blood
flow: CBF, mesenteric blood flow: MBF, iliac blood flow: IBF, and
renal blood flow: RBF) were collected on computer using a
customized data-acquisition system (Labview; National Instru-
ments; Austin, Texas, USA). The data were recorded at 100 Hz
for 10 second every minute during experiments. Total peripheral
conductance (TPC=CO/MAP) regional conductance (organ
conductance=organ blood flow/MAP) and stroke volume
(SV=CO/HR) were calculated.
Blood samples were taken the day before the induction of sepsis,
at the end of the sepsis control period, and every two hours during
intervention period for six hours. Urine was collected and sampled
every two hours throughout the experiment from the bladder
catheter using an automated fraction collector. However, no blood
samples were obtained at 24 hours to assess longer-term changes
in renal function.
At the end of the experiment, animals received intramuscular
gentamicn (150 mg), and all catheters were removed.
Effects of single (s-TP) or multiple (m-TP) doses of TP in
septic shock
Baseline measurements were collected for a 120 minute control
period before the induction of sepsis by intravenous infusion of live
Escherichia coli (E.coli) (3610
9 colony forming units) over five
minutes at midnight. Approximately 8 to 10 hours after the initial
bolus, animals typically reached the pre-defined cardiovascular
criteria for randomization (hyperdynamic sepsis): 10% decrease in
MAP, 50% increase in heart rate and 30% increase in CO.
After reaching the criteria for septic shock, the sheep in this
group (s-TP, n=7) were observed for a 120 minute pre-
intervention period before being randomly assigned to receive
an intravenous bolus injection of either TP (1 mg) or vehicle
(saline). MAP, CO, HR, vital organ blood flow (CBF, MBF, IBF
and RBF) and urinary output were continuously measured for
6 hours after the injection of TP. After 2 weeks recovery, the sheep
were crossed over to the other arm of the study.
A second group of sheep (m-TP, n=6) followed the same
protocol except that they received an intravenous bolus injection
of TP (1 mg), followed by two bolus injections of TP (0.5 mg) at 2
hourly intervals.
Although, doses of 2 mg are often given to patients of 80–
100 Kg in weight, concern that the standard human dose of 1 mg
might be excessive in 35 kg sheep led us to also study 0.5 mg doses
to improve clinical relevance. Additionally, to assess the impact of
repeated dosing, which could not be addressed by single bolus
administration, we studied the impact of two sequential boluses of
terlipressin of 0.5 mg. We reasoned that in 35 kg sheep they might
be the equivalent of two sequential boluses of 1 mg in man. The
objective of these studies was to elucidate how these clinically
common interventions may affect key regional circulations in
mammals.
Statistical analysis
The data in the table and text are presented as mean 6
standard deviation for 2 hours. In the figures of hemodynamic
changes, values are mean 6 standard deviation over 20 minutes of
the percentage change from the control values. Statistical analysis
was performed using SAS version 9.2 (SAS Institute Inc., Cary,
NC, USA). All outcomes were initially assessed for normality and
found to have sufficient symmetry to validate the use of repeat
measures mixed linear modeling with each sheep treated as a
random effect. Main effects were fitted for time, intervention
(vehicle, s-TP and m-TP) and an interaction between time and
intervention to ascertain if interventions behaved differently over
time. Whilst analysis was stratified by stage (control, sepsis and
intervention), particular attention was focused on reporting main
effects for the three interventions with post-hoc pairwise
comparisons adjusted by a Bonferroni correction. A two-sided p-
value of 0.05 was considered to be statistically significant.
Results
After the bolus injection of live E.coli, prior to the intervention
with s-TP or vehicle, all sheep reached the predefined criteria for
hyperdynamic sepsis within 10 hours. Hyperdynamic sepsis was
indicated by a 23% fall in MAP (93612 to 74612 mmHg,
p,0.05), peripheral vasodilatation (TPC increased from 4567t o
80628 mL/min/mmHg, p,0.05), a 40% increase in CO
(4.060.3 to 5.660.8 L/min, p,0.05) a doubling in HR (73611
to 14469 beats/min, p,0.05), a 29% decrease in SV (5569t o
3965 mL/beats, p,0.05) a halving in urine output, a 60%
decrease in creatinine clearance, a 37% increase in serum
creatinine and a 300% increase in blood lactate levels (Table 1,
Figure 1). All animals, however, survived the experiment.
During severe sepsis there was vasodilatation in all vascular
beds, as shown by the increases in each regional conductance. This
led to significant increases in renal blood flow (RBF) and
mesenteric blood flow (MBF) and similar trends for coronary
blood flow (CBF) and iliac blood flow (IBF) (Figures 1, 2, 3).
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Single dose TP (s-TP) (1 mg) returned MAP to control levels
(74612 to 8969 mmHg, p,0.0001), but the effect was temporary
and dissipated within four hours. Single dose TP also caused
transient decreases in HR, CO and TPC, but SV was not
improved. In particular, CO significantly decreased to below
control levels (Figure 1, Table 2). After s-TP, there was substantial
but transient vasoconstriction in the mesenteric circulation and a
significant decrease in MBF compared with vehicle (Figure 2,
Table 2). In the coronary vasculature s-TP caused vasoconstriction
and CBF significantly decreased compared with vehicle. IBF was
unchanged (Figure 3, Table 2).
After s-TP, there was a transient and minor decrease in renal
vascular conductance, but overall RBF increased due ot increased
perfusion pressure (Table 2). There was also a large increase in
UO over the first 2 hours following s-TP(Table 3).
The sepsis-induced decrease in creatinine clearance (Ccr) was
corrected by s-TP (Table 3). There were also increases in
filtration fraction (FF) and fraction excretion of sodium (FENa)
(Table 1).
Blood lactate was increased by the induction of sepsis and was
increased further by treatment with s-TP (to 3.9561.49 mmol/l)
(Figure 4, Table 3). There was a significant reduction in serum
potassium after s-TP (Figure 4).
Responses to multiple doses of Terlipressin (m-TP)
Following administration of E.coli, all sheep reached the
predefined criteria for sepsis, as described for the s-TP group
(Table 1, Figure 1).
The first injection of TP (1 mg) returned MAP to the pre-sepsis
control level, and the subsequent injections of TP (0.5 mg) at 2
hourly intervals increased MAP (Figure 1). The multiple injections
of TP caused similar, but more sustained, reductions in CO and
TPC than s-TP (Figure 1, Table 1).
Treatment with m-TP had differential effects on the regional
vasculature. As with s-TP, the greatest degree of vasoconstriction
occurred in the mesenteric and coronary circulations, with less
effect in the renal vasculature and little effect on the iliac vascular
bed. The effects on vasoconstriction in the mesenteric and
coronary vasculature were more sustained than with s-TP, but
Table 1. Renal functional and biochemical effects of terlipressin (TP) in severe sepsis.
Variable Intervention Control Septic TP 2 hours TP 4 hours TP 6 hours
FF (%) s-TP 38.5613.7 10.464.5 38.267.8 26.1616.4 14.466.2
FF (%) m-TP 32696 652 2 671 5 681 5 62
FF (%) vehicle 37.669.6 12.665.3 14.764.4 18.467.7 16.764.3
UO (ml/h) s-TP 61618 25611 3076158 138693 31615
UO (ml/h) m-TP 99623 27613 2296160 100634 60621
UO (ml/h) vehicle 73635 42642 24611 30611 43622
p-Cr (mmol/L) s-TP 96671 3 5 624 118615 119616 133625
p-Cr (mmol/L) m-TP 86610 127624 111623 101614 103618
p-Cr (mmol/L) vehicle 100611 131631 129627 127628 126627
CCr (ml/min) s-TP 62618 24688 5 620 62639 34615
CCr (ml/min) m-TP 54617 16614 40662 9 612 3468
CCr (ml/min) vehicle 64618 26614 31613 37612 37611
FENa (%) s-TP 0.3860.21 0.3560.23 2.5261.61 1.4660.96 0.3160.23
FENa (%) m-TP 0.4560.38 1.3361.27 2.2661.42 1.4560.64 0.6660.50
FENa (%) vehicle 0.5760.31 0.5260.41 0.1960.12 0.2260.19 0.1960.19
PaO2 (mmHg) s-TP 94.2611.1 83.767.8 84.366.1 83.667.9 84.365.6
PaO2 (mmHg) m-TP 100.169.3 90.463.3 94.466.5 94.768.2 9265.1
PaO2 (mmHg) vehicle 95.1613.3 83.9610.3 88.4610.1 88.1610.3 87.768.8
PaCO2 (mmHg) s-TP 36.262.9 33.166.2 34.463.6 32.962.2 31.761.5
PaCO2 (mmHg) m-TP 32.762.0 2861.7 31.661.4 31.861.1 31.062.5
PaCO2 (mmHg) vehicle 35.862.4 33.463.5 33.363.7 35.165.6 35.466.5
HCO3 (mmol/L) s-TP 27.963.1 26.063.8 24.762.6 23.962.5 25.961.4
HCO3 (mmol/L) m-TP 23.363.9 22.262.0 23.061.1 22.660.8 23.860.9
HCO3 (mmol/L) vehicle 27.961.3 25.362.0 26.262.5 27.062.9 27.162.8
Na (mmol/L) s-TP 144621 4 5 621 4 7 631 4 6 641 4 4 64
Na (mmol/L) m-TP 143621 4 4 631 4 5 661 4 3 651 4 2 65
Na (mmol/L) vehicle 144641 4 4 631 4 3 631 4 3 641 4 3 64
Cl (mmol/L) s-TP 111641 1 0 641 0 9 621 1 1 641 0 9 64
Cl (mmol/L) m-TP 111631 1 3 631 1 0 661 1 1 651 1 1 64
Cl (mmol/L) vehicle 111651 1 4 651 0 9 631 0 9 641 0 6 64
Filtration fraction=FF; urinary output=UO; plasma creatinine=p-Cr; creatinine clearance=CCr; fractional excretion of sodium=FENa.
doi:10.1371/journal.pone.0029693.t001
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period of observation, compared with sTP, mTP delivered
increases in mean coronary and mesenteric blood flow, and
MAP, while decreasing renal blood flow and total peripheral
conductance (Table 1).
The initial injection of TP significantly increased UO, but
despite further injections of TP there was a decrease in UO
towards sepsis levels over the following four hours (Table 2 and 3).
Administration of m-TP was associated with reduction in p-Cr,
which was more sustained than with s-TP as was the increase in
CCr (Table 1). Although FENa increased after the initial injection
of TP, this effect was not maintained (Table 3). However FF was
significantly greater with mTP than with sTP (Table 3) Finally,
blood lactate increased and serum potassium decreased with both
agents (Figure 4, Table 3). Despite, the increase in lactate, no
episodes of coronary or gut ischemia occurred during or after the
experiments.
Discussion
Key findings
In experimental severe hyperdynamic sepsis, a single bolus
injection of TP restored MAP to pre-sepsis levels and improved
renal function. However, TP also reduced CO by approximately
30% with slow return to control value over four hours, MBF by
approximately 40% with slow return to control values by three
hours and CBF by approximately 20%, an effect sustained over
the six hour observation period, increased plasma lactate and
lowered serum potassium. Treatment with multiple bolus
injections of TP caused qualitatively similar effects but with
significant attenuation of the s-TP induced beneficial renal effects
and relative preservation of cardiac output.
Comparison with previous studies
In patients with septic shock, AVP has been used as a
vasopressor to maintain arterial pressure [2,11,12] in septic
patients. Because of its longer half-life [11,12,14], TP has been
given as a bolus injection (typically 1 mg) every 4–6 hours [14].
Although in patients with septic shock bolus injection of TP
restores MAP, with improvement in CCr and UO [4,9,10,15], it
has a number of potential deleterious effects [6,16], such as
decreased oxygen delivery, and, in some cases, myocardial,
splanchnic and digital ischemia [12,17].
In our experimental animals, the systemic effects of TP were
consistent with those seen in patients with septic shock [4,9,10]
suggesting a degree of clinical relevance. Its temporary systemic
Figure 1. Systemic effects of a single bolus injection of TP multiple bolus injection of TP and vehicle in septic sheep. Single bolus
injection of TP (black circles); multiple bolus injection of TP (crosses); and vehicle (white circles). Heart rate, HR; mean arterial pressure, MAP; cardiac
output, CO; total peripheral conductance, TPC. Results are means 6 SD. * p,0.05 for comparisons between s-TP and vehicle at each intervention
point, + p,0.05 for comparisons between m-TP and vehicle at each intervention point, #p,0.05 for comparisons between m-TP and vehicle at each
intervention point,
*9 p,0.05 for comparisons between intervention and control within s-TP,
+9 p,0.05 for comparisons between intervention and
control within m-TP.
doi:10.1371/journal.pone.0029693.g001
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With repeated doses of TP, the effect on MAP appeared more
sustained compared with s-TP indicating that it may be feasible to
maintain a normal MAP in septic shock with frequent doses of TP.
Although continuous infusion of low-dose TP in septic sheep and
in patients with septic shock also maintained MAP [19–21], this
approach would make TP almost identical to AVP in terms of
hemodynamic and functional effects.
In clinical and experimental studies, single dose TP leads to
decreased cardiac output and oxygen delivery [4,10,12,15]. The
similar change seen in our experiments might have contributed
(together with mesenteric vasoconstriction) to the increase in blood
lactate concentration. With multi-dose TP, there were no
additional increases in lactate, suggesting that a multi-dose
protocol or an infusion might decrease these unwanted effects.
The large reduction in CO caused by TP is in accord with similar
effects seen in this model of sepsis with AVP [22], and the well
established ability of AVP to sensitize the arterial baroreflex, thus
causing a greater fall in CO and HR for a given rise in pressure
[23]. Importantly, all studies using single bolus TP in human and
experimental sepsis have shown a decrease in CO
[10,15,24,25,26,27] of similar magnitude to what was found in
our study. In the only study we identified that assessed the effect of
multiple boluses [26] of 1 mg in sheep, the systemic hemodynamic
findings, urine output findings and lactate effects were almost
identical.
Renal effects of Terlipressin
A single dose of TP temporary returned RVC towards control
levels, without a change in RBF, and transiently improved renal
function. With multiple doses of TP the hemodynamic effects and
improvement in Ccr were attenuated but sustained, and the effect
on urine output remained transient. Similarly, in patients with
septic shock, bolus injection of TP or AVP improved Ccr
[4,10,12,15]. This effect may be explained by preferential
vasoconstriction of the efferent arterioles, where there is a higher
density of AVP V1 receptors [28]. This effect would lead to an
increase in glomerular filtration pressure, Ccr and FF and decrease
in RVC as seen in the present study. These effects of TP and AVP
are similar to those of angiotensin II [29]. In addition, the increase
in MAP caused by TP might have contributed to the increased
UO and FENa. However, this effect was greater than that seen
with equipressor doses of noradrenaline and adrenaline [30,31],
indicating that the improvement in renal function is not simply
Figure 2. Effects on renal and mesenteric vasculatures of a single bolus injection of TP multiple bolus injection of TP and vehicle in
septic sheep. Single bolus injection of TP (black circles); multiple bolus injection of TP (crosses); and vehicle (white circles). Renal blood flow, RBF;
renal vascular conductance, RVC; mesenteric blood flow MBF; mesenteric vascular conductance, MVC. Results are means 6 SD. * p,0.05 for
comparisons between s-TP and vehicle at each intervention point, + p,0.05 for comparisons between m-TP and vehicle at each intervention point,
*9 p,0.05 for comparisons between intervention and control within s-TP,
+9 p,0.05 for comparisons between intervention and control within m-TP.
doi:10.1371/journal.pone.0029693.g002
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potassium observed after s-TP and m-TP are consistent with
previous report of increased urinary excretion of potassium [32].
The effects of Terlipressin on vital organ blood flow
TP has a potent splanchnic vasoconstrictor effect in non-septic
states [33,34], and a similar action has been proposed in sepsis
[12,35]. In these conscious animals with severe hyperdynamic
sepsis, TP significantly decreased MBF suggesting that that, even
in the hyperdynamic state, TP might induce excessive mesenteric
vasoconstriction. In sepsis, a high coronary blood flow appears
essential to preserve cardiac oxygen metabolism [36,37]. Our
findings that TP caused coronary vasoconstriction and rapidly
reduced CBF in a model of sepsis suggests that in patients with
hyperdynamic sepsis, and at risk of ischemic heart disease,
treatment with TP should be used with caution to avoid excessive
coronary vasoconstriction, myocardial ischemia and dysfunction
[19,38,39]. There are several reports describing adverse vasocon-
strictor effects of TP on lower limbs, digits and skin, resulting in
amputations and skin necrosis [6,11,13]. In the present study, TP
did not cause excessive vasoconstriction in the iliac vascular bed,
but skin blood flow was not measured and no necrosis was
observed during or following the 6 hour intervention period.
Strengths and limitations
To our knowledge, this is the first study to report on the effects
of a bolus of 1 mg of TP on mesenteric blood flow in awake
hyperdynamic septic animals and to report on the effects of such
bolus and repeated doses of TP on coronary, renal and iliac blood
flow in septic animals. In addition, it is the first to provide
controlled information on the effects of TP on renal function
during hyperdynamic sepsis. Finally, our model of hyperdynamic
sepsis simulates the typical clinical human phenotype suggesting a
degree of clinical relevance. However, this study has several
important limitations. We did not measure the effect of TP on
oxygen extraction because of the difficulty of chronically
maintaining patency of venous sampling cannulae. We did not
measure the effect of TP on all aspects of vital organ function.
However, the information of stroke volume provides a clinically
relevant measure of its cardiac effect, lactate blood levels provide a
clinically relevant indirect assessment of splanchnic function and
urine output, serum creatinine levels, filtration fraction and
fractional excretion of sodium all provide a clinically relevant
assessment of kidney function. We did not study the effects of
continuous TP infusion, we considered we would assess the effects
of TP when given in its most commonly prescribed and
manufacturer recommended dosage schedule first. Although
Figure 3. Regional effects on coronary and iliac vasculatures of a single bolus injection of TP multiple bolus injection of TP and
vehicle in septic sheep. Single bolus injection of TP (black circles); multiple bolus injection of TP (crosses); and vehicle (white circles). Coronary
blood flow, CBF; coronary vascular conductance, CVC; iliac blood flow IBF; iliac vascular conductance, IVC. Results are means 6 SD. * p,0.05 for
comparisons between s-TP and vehicle at each intervention point, + p,0.05 for comparisons between m-TP and vehicle at each intervention point,
*p ,0.05 for comparisons between intervention and control within s-TP,
+, p,0.05 for comparisons between intervention and control within m-TP.
doi:10.1371/journal.pone.0029693.g003
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of TP report a rapid response (24–48 hours). Thus, short-term
changes in hemodynamics are likely representative of the early
effect of TP in general. We can however, make no comment on
the longer term effects of the drug.
Conclusions
In experimental hyperdynamic severe sepsis, treatment with TP
returned MAP to control levels, increased renal vascular resistance
and improved renal function. However, it also decreased CO by
approximately one third, mesenteric and coronary blood flow by
similar percentages, and caused hyperlactatemia and hypokalemia.
These data imply that caution should be applied when prescribing
TP in septic patients at risk of coronary or mesenteric ischemia;
increase our understanding of the regional hemodynamic effects of
TP in severe sepsis and assist clinicians in their selection of optimal
Table 2. Pair-wise comparisons for main effects during the
intervention periodˆ.
Variable Group1 Group2 % Difference SE P-value*
CBF mTP sTP 0.21 0.03 ,0.0001
CBF Vehicle mTP 0.10 0.03 0.010
CBF Vehicle sTP 0.30 0.02 ,0.0001
CO mTP sTP 20.09 0.03 0.002
CO Vehicle mTP 0.27 0.03 ,0.0001
CO Vehicle sTP 0.19 0.02 ,0.0001
CVP mTP sTP 20.22 0.05 ,0.0001
CVP Vehicle mTP 0.74 0.05 ,0.0001
CVP Vehicle sTP 0.51 0.04 ,0.0001
HR mTP sTP 0.22 0.04 ,0.0001
HR Vehicle mTP 0.08 0.04 0.11
HR Vehicle sTP 0.30 0.03 ,0.0001
IBF mTP sTP 20.18 0.07 0.04
IBF Vehicle mTP 0.45 0.07 ,0.0001
IBF Vehicle sTP 0.27 0.05 ,0.0001
MAP mTP sTP 0.08 0.01 ,0.0001
MAP Vehicle mTP 20.17 0.01 ,0.0001
MAP Vehicle sTP 20.09 0.01 ,0.0001
MBF mTP sTP 0.12 0.04 0.002
MBF Vehicle mTP 20.04 0.04 0.68
MBF Vehicle sTP 0.08 0.03 0.005
RBF mTP sTP 20.16 0.04 ,0.0001
RBF Vehicle mTP 20.01 0.04 1.0
RBF Vehicle sTP 20.17 0.03 ,0.0001
RVC mTP sTP 20.33 0.04 ,0.0001
RVC Vehicle mTP 0.29 0.04 ,0.0001
RVC Vehicle sTP 20.04 0.03 0.56
TPC mTP sTP 20.29 0.04 ,0.0001
TPC Vehicle mTP 0.69 0.04 ,0.0001
TPC Vehicle sTP 0.40 0.03 ,0.0001
ˆsingle dose terlipressin=sTP; multiple dose terlipressin=mTP; Group numbers
indicate nature of comparison. A positive difference means that group one had
a higher value than group 2. The number under %difference represents the
percentage of difference between the two groups. A negative difference means
that group 2 had a higher value. For example, mean arterial pressure (MAP) was
higher with mTP or STP than vehicle. SE=standard error; CBF=coronary blood
flow; CO=cardiac output; CVP=central venous pressure; HR=heart rate;
IBF=iliac blood flow; MAP=mean arterial pressure; MBF=mesenteric blood
flow; RBF=renal blood flow; RVC=renal vascular conductance; TPC=total
peripheral conductance.
*All values represent P values after Bonferroni adjustment.
doi:10.1371/journal.pone.0029693.t002
Table 3. Pair-wise comparisons of terlipressin (TP) effects
during the intervention period‘.
Variable Group1 Group2 Difference SE P-value*
CCr mTP sTP 224.38 5.37 0.0001
CCr Vehicle mTP 20.82 5.37 1.0
CCr Vehicle sTP 225.20 4.79 ,0.0001
Cl mTP sTP 0.77 1.02 1. 0
Cl Vehicle mTP 22.91 1.02 0.02
Cl Vehicle sTP 22.14 0.78 0.03
FENa% mTP sTP 0.03 0.25 1.0
FENa% Vehicle mTP 21.25 0.25 ,0.0001
FENa% Vehicle sTP 21.23 0.23 ,0.0001
FF% mTP sTP 29.35 2.37 0.0009
FF% Vehicle mTP 20.33 2.37 1.0
FF% Vehicle sTP 29.68 2.27 0.0003
HCO3 mTP sTP 21.46 0.67 0.10
HCO3 Vehicle mTP 3.94 0.67 ,0.0001
HCO3 Vehicle sTP 2.49 0.56 0.0002
K mTP sTP 20.41 0.13 0.008
K Vehicle mTP 1.06 0.13 ,0.0001
K Vehicle sTP 0.65 0.10 ,0.0001
Lac mTP sTP 20.88 0.40 0.10
Lac Vehicle mTP 20.55 0.40 0.51
Lac Vehicle sTP 21.43 0.31 0.0001
Na mTP sTP 22.85 1.05 0.03
Na Vehicle mTP 0.37 1.05 1.0
Na Vehicle sTP 22.48 0.82 0.01
PCO2 mTP sTP 21.66 1.02 0.33
PCO2 Vehicle mTP 3.76 1.02 0.002
PCO2 Vehicle sTP 2.10 0.82 0.04
P-Cr mTP sTP 218.20 6.53 0.02
P-Cr Vehicle mTP 22.20 6.53 0.004
P-Cr Vehicle sTP 4.00 5.28 1.0
PO2 mTP sTP 8.50 2.22 0.001
PO2 Vehicle mTP 28.23 2.22 0.002
PO2 Vehicle sTP 0.27 1.71 1.0
UO mTP sTP 224.42 24.39 0.97
UO Vehicle mTP 2101.86 24.39 0.0004
UO Vehicle sTP 2126.29 21.68 ,0.0001
‘single dose terlipressin=sTP; multiple dose terlipressin=mTP; Group numbers
indicate nature of comparison. A positive difference means that group one had
a higher value than group 2. A negative difference means that group 2 had a
higher value. SE=standard error; CCr = creatinine clearance in ml/min; Cl =
chloride in mmol/L; FENa=fractional excretion of sodium as %; FF=filtration
fraction as %; HCO3 = bicarbonate in mmol/L; K=potassium in mmol/L;
Lac=lactate in mmol/L; Na=sodium in mmol/L; PCO2=partial arterial pressure
of carbon dioxide in mmHg; P-Cr=plasma creatinine in mmol/L; PO2= partial
arterial pressure of oxygen in mmHg; UO=urine output in ml/hr.
*All values represent P values after Bonferroni adjustment.
doi:10.1371/journal.pone.0029693.t003
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